YOU DON’T HAVE TO WAIT TO DROP TESTOSTERONE (T)
FIRMAGON® is the only ADT proven to drop T BY 88% ON DAY 11,2
Change in T Levels From Baseline Over 28 Days1
Use of the LHRH agonist leuprolide led to an initial 65% increase in testosterone over the first 3 days compared to a reduction of 94% with FIRMAGON.2,3
The pivotal phase 3 trial (CS21) was a 3-armed, randomized (1:1:1), active-controlled, open-label, parallel-group, 12-month clinical study of FIRMAGON compared to leuprolide acetate (Lupron Depot®).3 Serum levels of testosterone were measured at screening, on days 0, 1, 3, 7, 14, and 28 in the first month, and then monthly until the end of the study.1
FIRMAGON was shown to maintain testosterone suppression below castration level (≤50 ng/dL) during 12 months of treatment.
- Proportion of patients with testosterone ≤50 ng/dL
- Serum levels of testosterone, prostate-specific antigen (PSA), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) over time
- Percentage change in PSA from baseline
Abbreviations: ADT = androgen deprivation therapy; FSH = follicle-stimulating hormone; GnRH = gonadotropin-releasing hormone; LH = luteinizing hormone; LHRH = luteinizing hormone-releasing hormone; PSA = prostate-specific antigen; T = testosterone.
Lupron Depot is a registered trademark of ABBVIE ENDOCRINE INC.
Help make the most of your patient's treatment experience
Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.
REFERENCES: 1. FIRMAGON® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.